Study Design, Baseline and Open-Label Results from XTEND-CIU: A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab through 48 Weeks in Patients with Chronic Idiopathic Urticaria
In: journal of allergy and clinical immunology, Jg. 139 (2017), Heft 2, S. AB271
serialPeriodical
Zugriff:
Titel: |
Study Design, Baseline and Open-Label Results from XTEND-CIU: A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab through 48 Weeks in Patients with Chronic Idiopathic Urticaria
|
---|---|
Autor/in / Beteiligte Person: | Casale, Thomas B. ; Scarupa, Mark D. ; Holden, Michael ; Trzaskoma, Benjamin L. ; Antonova, Evgeniya ; Win, Patrick H. |
Link: | |
Zeitschrift: | journal of allergy and clinical immunology, Jg. 139 (2017), Heft 2, S. AB271 |
Veröffentlichung: | 2017 |
Medientyp: | serialPeriodical |
ISSN: | 0091-6749 (print) |
Sonstiges: |
|